ABSTRACT The increasing prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with spike protein mutations raises concerns that antibodies elicited by natural infection or vaccination and therapeutic monoclonal antibodies will become less effective. We show that convalescent-phase sera neutralize pseudotyped viruses with the B.1.1.7, B.1.351, B.1.1.248, COH.20G/677H, 20A.EU2, and mink cluster 5 spike proteins with only a minor loss in titer. Similarly, antibodies elicited by Pfizer BNT162b2 vaccination neutralized B.1.351 and B.1.1.248 with only a 3-fold decrease in titer, an effect attributable to E484K. Analysis of the Regeneron monoclonal antibodies REGN10933 and REGN10987 showed that REGN10933 has lost neutralizing activity against the B.1.351 and B.1.1.248 pseudotyped viruses, and the cocktail is 9- to 15-fold decreased in titer. These findings suggest that antibodies elicited by natural infection and by the Pfizer vaccine will maintain protection against the B.1.1.7, B.1.351, and B.1.1.248 variants but that monoclonal antibody therapy may be less effective for patients infected with B.1.351 or B.1.1.248 SARS-CoV-2.
【저자키워드】 SARS-CoV-2, B.1.351, neutralization, Spike protein, B.1.1.7, Pfizer BNT162b2, REGN10933, REGN10987, B.1.1.248, COH.20G/677H, 20A.EU2, mink cluster 5, 【초록키워드】 viruses, Vaccine, coronavirus, vaccination, therapy, Mutation, antibody, B.1.351, monoclonal antibody, variant, severe acute respiratory syndrome Coronavirus, variants, monoclonal antibody therapy, Spike protein, BNT162b2, Pfizer, Prevalence, Neutralizing activity, Pseudotyped virus, B.1.1.7, titer, sera, therapeutic, Patient, Cluster, E484K, REGN10933, REGN10987, respiratory, Pseudotyped viruses, natural infection, cocktail, Spike proteins, a minor, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, minor, Regeneron, effective, decrease, neutralize, neutralized, raise, less, maintain, elicited, 【제목키워드】 spike,